Adverse events after adjuvant radiation therapy for Dupuytren's disease in the DEPART randomized trial.

This study reports adverse events after adjuvant radiotherapy in patients with Dupuytren's disease. Patients for planned limited fasciectomy, collagenase injection or percutaneous needle fasciotomy were enrolled in a randomized controlled trial. Sixty patients were randomized to observation or radiotherapy (30 Gy, 10 fractions) starting within 4 days of the procedure.

A multicentre implementation trial of an Artificial Intelligence-driven biomarker to inform Shared decisions for androgen deprivation therapy in men undergoing prostate radiotherapy: the ASTuTE protocol.

Background: Androgen deprivation therapy (ADT) improves outcomes in men undergoing definitive radiotherapy for prostate cancer but carries significant toxicities. Clinical parameters alone are insufficient to accurately identify patients who will derive the most benefit, highlighting the need for improved patient selection tools to minimize unnecessary exposure to ADT's side effects while ensuring optimal oncological outcomes. The ArteraAI Prostate Test, incorporating a multimodal artificial intelligence (MMAI)-driven digital histopathology-based biomarker, offers prognostic and predictive information to aid in this selection.